<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226654</url>
  </required_header>
  <id_info>
    <org_study_id>9812</org_study_id>
    <secondary_id>2R01NS029029-16A1</secondary_id>
    <nct_id>NCT01226654</nct_id>
  </id_info>
  <brief_title>Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis</brief_title>
  <official_title>Quantitative MR Imaging and Proton Spectroscopy in MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to detect changes in the brain that may be associated
      with multiple sclerosis. Results will be compared to age matched controls. Investigators will
      assess lesions by measuring T2 and T1 enhanced lesion volumes and magnetization transfer
      ratio histogram parameters (MTRHP) in patients with relapsing-remitting and
      secondary-progressive disease. This data will be correlated to total brain parenchymal volume
      as well as identifying the effect of MS lesions on the gray and white matter, volumetric
      disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery
      of neuropsychological tests. Quantitative analysis of whole brain N-acetylaspartate (WBNAA),
      a reproducible measure of viable neuron number, using 1H MRS and compare the results to
      age-matched controls over duration of 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 1991</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the MS lesions using Magnetization transfer ratio histogram parameters and compare it to total brain parenchymal volume</measure>
    <time_frame>5 years</time_frame>
    <description>1) Lesions will be assessed by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative analysis of whole brain N-acetylaspartate (WBNAA)</measure>
    <time_frame>5 years</time_frame>
    <description>Quantitative analysis of whole brain N-acetylaspartate (WBNAA), a reproducible measure of viable neuron number, using 1H MRS and compare the results to age-matched controls over duration of 5 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MS Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Magnetic Resonance Imaging EDSS</description>
    <arm_group_label>MS Patients</arm_group_label>
    <arm_group_label>Healthy Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with known MS diagnosis

          2. Age 7-110 years

          3. Males or females

        Exclusion Criteria:

          1. Medically unstable

          2. Artificial implants in the body

          3. Pregnant

        Normal Controls
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yulin Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ge Y, Zohrabian VM, Osa EO, Xu J, Jaggi H, Herbert J, Haacke EM, Grossman RI. Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging. 2009 May;29(5):1190-4. doi: 10.1002/jmri.21758.</citation>
    <PMID>19388109</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quantitative Imaging of Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

